ðŸ“Œ Total Documents: 4,000
ðŸ“Œ Columns in Data: Trial ID, Title, Condition, Intervention, Study Type, Phase, Summary, Eligibility, Enrollment, Cleaned_Summary

ðŸ“œ First 5 Documents:

   Trial ID                                                                                                       Title                                                                                                                                                                                                                                                                           Condition                                                                                                                                                                                                                                    Intervention     Study Type  Phase                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Summary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Eligibility  Enrollment                                                                                                                                                                                                                                                                                                                                                                                                                Cleaned_Summary
NCT02458040                    Clinical Benefit of Genetic Biomarkers for Guiding Treatment Decisions in Oncology Drugs                                                                                                                                                                                                                                                                           Neoplasms                                                                                                                                                                                                                      Drug selected in the study  OBSERVATIONAL    NaN                                                                                                                                                                                                                                                                                                                                                                    This study is a meta-epidemiological study which aim is to quantify the clinical benefit of the biomarker-based strategy compared to conventional strategy across all drugs with such a strategy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Inclusion Criteria:\n\n* phase II or III randomized clinical trials\n* including patients with one of the drug-biomarker-indication triplet studied\n* evaluating treatment effect in biomarker-defined strata (either in biomarker-positive patients, in biomarker-negative patients or in both strata).\n* reporting OS or PFS or DFS\n\nExclusion Criteria:\n\n* None         0.0                                                                                                                                                                                                                                                                                     study metaepidemiological study aim quantify clinical benefit biomarkerbased strategy compared conventional strategy across drugs strategy
NCT01234740                         Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Tumor, Tumors Metastatic to Brain, Adult Anaplastic Oligoastrocytoma bafetinib, microdialysis, pharmacological study, liquid chromatography, mass spectrometry, laboratory biomarker analysis, protein expression analysis, western blotting, immunohistochemistry staining method, therapeutic conventional surgery INTERVENTIONAL PHASE1                                                                                                                                                                                                                                                                                                                         RATIONALE: Bafetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.\n\nPURPOSE: This clinical trial studies bafetinib in treating patients with recurrent high-grade glioma or brain metastases.                                                                                                                                                                                               Inclusion Criteria:\n\n* Patients must have radiographic findings consistent with either:\n\n  * Recurrent high-grade glioma, or\n  * Metastatic disease to the brain that has progressed after treatment with whole brain radiation therapy or stereotactic radiosurgery; patients who have a resectable brain metastasis as the only site of disease (i.e., no evidence of systemic disease), are not eligible to participate\n* Patients who are in need of a surgical debulking or a stereotactic biopsy for the purpose of diagnosis or differentiating between tumor progression versus treatment-induced effects following radiation therapy +/- chemotherapy will be eligible to participate in the microdialysis part of the study prior to beginning cycle 1 of bafetinib if the study neurosurgeon thinks there is a likelihood of being able to place the microdialysis catheter into residual tumor (enhancing brain tissue)\n* Patients who choose not to participate in the microdialysis part of the study may enroll in the study and start treatment at cycle 1 of bafetinib\n* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for 3 months following duration of study participation; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately\n* Patients must have a Karnofsky Performance Status (KPS) \>= 60%\n* If corticosteroids are required for controlling cerebral edema, patients must be on a stable dose for at least 1 week prior to enrollment\n* Patients must not be taking any hepatic enzyme-inducing anticonvulsants (phenytoin, carbamazepine, phenobarbital, primidone, oxcarbazepine) for at least 2 weeks prior to enrollment\n* Absolute neutrophil count \>= 1500 cells/mm\^3\n* Platelet count \>= 100,000 cells/mm\^3\n* Total bilirubin =\< 2.0 mg/dl\n* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) =\< 3 times the institutional upper limit of normal\n* Alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase \[SGPT\]) =\< 3 times the institutional upper limit of normal\n* Serum creatinine =\< 1.5 x the institutional upper limit of normal\n* QTc interval \< 480 msec on electrocardiogram (ECG)\n* All subjects must have the ability to understand and the willingness to sign a written informed consent\n* Patients must have recovered from any toxicity of prior therapies (including brain radiation); an interval of at least 6 weeks must have elapsed since the completion of a nitrosourea-containing chemotherapy regimen; patients who have undergone a recent craniotomy cannot begin bafetinib until at least 2 weeks after the surgery\n\nExclusion Criteria:\n\n* Patients who are currently receiving chemotherapy or are enrolled in another treatment clinical trial\n* Patients with a coagulopathy or bleeding disorder\n* Patients on anticoagulant drug therapy or medications that inhibit platelet function, such as ibuprofen or other non-steroidal anti-inflammatory drugs\n* Clinically evident congestive heart failure \> class II of the New York Heart Association (NYHA) guidelines\n* Clinically significant cardiac arrhythmias\n* Patients taking a drug that can prolong the QT interval; if a potential study patient is taking one of the prohibited drugs but s/he can safely stop it, then a washout period of \>= 7 days is required prior to starting bafetinib\n* History or signs of active coronary artery disease with or without angina pectoris\n* Patients who have a serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol or may not be able to comply with the safety monitoring requirements of the study\n* Human immunodeficiency virus (HIV)-positive patients receiving anti-retroviral therapy are excluded from the study due to the possibility of pharmacokinetic (PK) interactions with bafetinib; however, patients will not be routinely screened for HIV\n* Female patients who are pregnant or breast-feeding\n* Active, clinically significant serious infection requiring treatment with antibiotics, anti-virals or anti-fungals\n* Patients who have not recovered from the toxicities of prior chemotherapy or radiotherapy         7.0                                                                                                                                                                                                                                     rationale bafetinib may stop growth tumor cells blocking enzymes needed cell growth purpose clinical trial studies bafetinib treating patients recurrent highgrade glioma brain metastases
NCT00514540                                         Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer                                                                                                                                                                                                                                                                     Prostate Cancer                                                                                                                                                                                                    Docetaxel, Carboplatin, Etoposide, Cisplatin INTERVENTIONAL PHASE2 The goal of this clinical research study is to learn about how effective 2 chemotherapy drugs carboplatin (Paraplatin) plus docetaxel (Taxotere) in the treatment of patients with anaplastic prostate cancer. Patients who continue to have advanced disease will be switched to etoposide (VePesid) plus cisplatin (Platinol-AQ) to study how effective this second line of chemotherapy is in the treatment of patients iwth anaplastic prostate cancer.\n\nThe side effects, characteristics of patients who respond, and overall survival will also be studied. Inclusion Criteria:\n\n1. Patient must have androgen independent Stage IV prostate cancer, with anaplastic features as defined by at least one of the following: a) Histologic evidence of small cell(pure/mixed), locally advanced or metastatic; b) Any of the following at Dx: exclusive visceral mets, predominant lytic mets, bulky ( \>/= 5 cm) lymphadenopathy, or bulky ( \>/= 5 cm) high-grade (Gleason \>/= 8) tumor mass in the prostate/pelvis c) Low prostate-specific antigen (PSA) at diagnosis (Dx) + high volume bone mets.\n2. (#1 cont'd) d) Neuroendocrine markers in histology (+ Chromogranin A and/or Synaptophysin) or serum (abnl high serum Chromogranin A or Bombesin) at Dx or at progression plus any of the following: elevated serum lactate dehydrogenase (LDH), malignant HyperCa+, or elevated serum Carcinoembryonic Antigen (CEA) in the absence of other etiologies. e) Short interval (\< 6 months) to androgen-independent progression following initiation of hormonal therapy with or without presence of neuroendocrine markers.\n3. Patients with small cell carcinoma on histology are not required to have received prior androgen deprivation therapy (ADT). All other patients must have evidence of disease progression while on ADT or an unsatisfactory response to \>/= 1 month of castration, as defined by lack of symptom control and/or serum tumor marker response of \< 20% (confirmed by a second value drawn on a different day).\n4. Zubrod performance status of \</= 2.\n5. Normal EKG or, if EKG is suggestive of cardiomyopathy, patient has a resting Left Ventricular Ejection Fraction (LEVF) \>/= 50% within 4 months.\n6. Patient has all of the following pretreatment laboratory data within 14 days before registration: â€¢ Absolute neutrophil count (ANC) \>=1,500/mm\^3.(unless due to bone marrow infiltration by tumor, in which case ANC \>/= 500/mm\^3 are allowed). â€¢ Platelets \>=100,000/mm\^3 (unless due to bone marrow infiltration by tumor, in which case platelets \>/= 20,000/mm\^3 are allowed)\n7. (#7 cont'd) â€¢ Total bilirubin \</= 2 mg/dl; if greater, conjugated bilirubin should be \<= 1.0 mg/dL, â€¢ serum glutamate pyruvate transaminase (SGPT) (ALT) and/or serum glutamate oxaloacetate transaminase (SGOT) (AST) \</= 4 times the upper limit of normal (ULN). â€¢ Creatinine clearance \>/= 40 (either measured or calculated by Cockcroft formula) â€¢ Castrate levels of serum testosterone (\</= 50ng/mL) if no small cell elements on histology. (If small cell, testosterone \> 50ng/mL)\n8. Patient has given voluntary written informed consent before performance of any study-related procedure not part of standard medical care.\n\nExclusion Criteria:\n\n1. Immunotherapy or chemotherapy within four weeks (nitrosoureas within six weeks) of registration.\n2. 2 or more prior chemotherapy regimens (ketoconazole, aminoglutethimide or dutasteride do not count as chemotherapy for this trial).\n3. Prior Platinum, Etoposide, or Taxane-based therapy that was completed less than 6 months from registration.\n4. Samarium-153 within four weeks of registration, or Strontium-89 within 12 weeks of registration. Patients who have received 2 or more doses of bone-seeking radioisotopes are not eligible.\n5. Patient has not recovered from all serious toxic effects of previous chemotherapy, radiation or antibody therapy, or from previous major surgery.\n6. Patients with symptomatic and untreated brain metastases or central nervous system disease will be excluded. Patients with untreated, asymptomatic brain metastasis (not requiring corticosteroid treatment for control of central nervous system (CNS) symptoms) may be eligible, at the discretion of the MDACC Principal Investigator. Patients with treated brain metastases are eligible.\n7. Patient with significant atherosclerotic disease, as defined by: a) myocardial infarction within six months of enrollment. Current uncontrolled/unstable angina pectoris or electrocardiographic evidence of acute ischemia b) clinically significant ventricular arrhythmias c) symptomatic congestive heart failure (NYHA Class III)\n8. Patient has \>= Grade 2 peripheral neuropathy.\n9. Patient has renal insufficiency with cranial cruciate ligament (CrCL) \< 40 ml/min with non-correctable etiologies.\n10. Patient has an uncontrolled intercurrent illness (e.g., active infection).\n11. Patient has another serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the patient's ability to provide informed consent or with the completion of treatment according to this protocol.       121.0 goal clinical research study learn effective 2 chemotherapy drugs carboplatin paraplatin plus docetaxel taxotere treatment patients anaplastic prostate cancer patients continue advanced disease switched etoposide vepesid plus cisplatin platinolaq study effective second line chemotherapy treatment patients iwth anaplastic prostate cancer side effects characteristics patients respond overall survival also studied
NCT01329640 Feasibility Study of Metronomic Chemotherapy for Locally Advanced Her2- Positive Breast Cancer (TraQ-Me 01)                                                                                                                                                                                                                                        Locally Advanced HER2-positive Breast Cancer                                                                                                                                                                                   Drug: Paclitaxel; trastuzumab; doxorrubicin; cyclophosphamide INTERVENTIONAL PHASE2                                                                                                                                                                                                                                                                                                                                              The purpose of this study is to evaluate the safety, effectiveness and cost-effectiveness of metronomic chemotherapy combined with trastuzumab as neoadjuvant therapy for locally advanced HER2-positive breast cancer.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Inclusion Criteria:\n\n* Diagnosis of locally advanced breast cancer\n* T \> 2 cm (any N), or any T and positive node(needle biopsy is required if tumor size is less than 2cm)\n* Non-metastatic disease confirmed by computerized tomography and bone scan\n* HER2 positive by IHC (+++) and/or Fish (+) according to international definitions (ASCO 2007)\n* Normal left ventricular ejection fraction (LVEF)\n* Indication of preoperative chemotherapy\n* multifocal tumors acceptable provided that the largest tumor is Her2-positive\n* ECOG 0-1\n\nExclusion Criteria:\n\n* Another malignancy within the last 5 years (except curatively treated skin carcinoma, in situ cervix carcinoma, in situ ductal carcinoma of the breast, or in situ lobular carcinoma of the breast)\n* Clinically significant comorbidities such as cardiovascular diseases, COPD, renal or liver impairment, psychiatric disorders\n* LVEF value below institutional limits of normal range\n* Detected or suspected distant metastasis\n* Neutrophils lower than 1,500/ÂµL, platelets lower than 100,000/ÂµL, hemoglobin lower than 10 g/dL, AST higher than 2.5x upper limit of normal (ULN), total bilirubin higher than ULN, alkaline phosphatase more than 1.5x ULN         9.0                                                                                                                                                                                                                                                     purpose study evaluate safety effectiveness costeffectiveness metronomic chemotherapy combined trastuzumab neoadjuvant therapy locally advanced her2positive breast cancer
NCT00424840                          Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy                                                                                                                                                                                                                                                                         Lung Cancer                                                                                                                                      Bortezomib 1.3 mg/m2, Bortezomib 1.6 mg/m2, Bortezomib 1.8 mg/m2, Carboplatin AUC 6, Bevacizumab, Taxotere INTERVENTIONAL PHASE1                                      A pilot trial of combination of bortezomib, bevacizumab and carboplatin as first line therapy in patients with metastatic Non-Small Cell Lung Cancer (NSCLC). Phase I and II study of this combination in first line setting will be conducted in order to properly estimate the efficacy and safety of this regimen. This will form the basis for future studies comparing this combination to what is now considered standard regimen for first line therapy in patients with NSCLC, carboplatin, paclitaxel and bevacizumab.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Inclusion Criteria:\n\n* Histologically confirmed SCLC (adeno- and large cell, anaplastic carcinoma and broncho-alveolar-carcinoma). Patients with squamous-cell histology are eligible with extra thoracic or peripheral lung lesions only.\n* Sputum cytology alone not acceptable evidence of cell type. Cytologic specimens obtained by brushing, washings, or needle aspiration of defined lesions will be acceptable. Mixed tumors will be categorized by the predominant cell type unless a small cell anaplastic elements are present, in which case the patient is ineligible.\n* Stage III B because of pleural effusion or Stage IV disease\n* Measurable disease.\n* Age: 18 years or older\n* No history of thrombotic, hemorrhagic, or coagulopathy disorders\n* international normalized ratio (INR\<1.5) and a prothrombin time (PTT) no greater than normal limits of normal within 1 week prior to registration. NB: subjects with lung cancer placed on anticoagulant therapy for a thrombotic event are not eligible for this study.\n* No gross hemoptysis (defined as bright red blood of Â½ teaspoon or more)\n* No central nervous system (CNS) or brain metastasis\n* Laboratory Criteria (completed \<2 weeks before enrollment):\n\n  * Hematologic: white blood cell (WBC) \> 3500/mm3 or absolute neutrophil count (ANC) \> 1500/mm3 and platelet count \> 100 000/ mm3;\n  * Hepatic: Total bilirubin \< 1.5 mg/dl\n  * Renal: Creatinine \< 1.5 mg/dl. or calculated\n  * Creatinine clearance \> 45 ml/min (NB: Urine protein:creatinine ratio in exclusion criteria)\n* Eastern Cooperative Oncology Group (ECOG) performance status \< 2\n* Be free of active infection.\n* Be available for active follow up.\n* No prior chemotherapy for metastatic disease.\n* Be disease free for \> 5 years if they had a prior second malignancy other than treated basal cell carcinoma or squamous cell skin cancer, or carcinoma in situ of the cervix.\n* Female subject post-menopausal; surgically sterilized or willing to use an acceptable method of birth control for the duration of the study. Male subject agrees to use an acceptable method for contraception for the duration of the study.\n\nExclusion Criteria:\n\n* CNS or brain metastasis\n* Patient has = or greater Grade 2 peripheral neuropathy within 14 days before enrollment.\n* Known previous sensitivity reactions with boron, or mannitol,\n* Patients with known HIV positivity\n* Myocardial infarction within 6 months prior to enrollment or has New York Hospital Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Any ECG abnormality at Screening has to be documented by the investigator as not medically relevant.\n* Blood pressure of \>150/100 mmHG\n* History of myocardial infarction or stroke within 6 months\n* Clinically significant peripheral vascular disease\n* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, anticipation of need for major surgical procedure during the course of the study.\n* Minor surgical procedure such as fine needle aspirations or core biopsies within 7 days prior to day 0\n* Urine protein: Creatinine ratio \> 1.0 at screening\n* History of abdominal fistula, gastrointestinal perforation, or intraabdominal abscess within 6 months prior to Day 0\n* Serious, non-healing wound, ulcer, or bone fracture\n* Lung carcinoma or any histology in close proximity to a major vessel or cavitation\n* Female subject is pregnant or breast-feeding. Confirmation that the subject is not pregnant. Pregnancy testing is not required for post-menopausal or surgically sterilized women.\n* Patient has received other investigational drugs with 14 days before enrollment or is expected to participate in an experiment drug study during this study treatment.\n* Serious medical or psychiatric illness likely to interfere with participation in this clinical study.        12.0                                     pilot trial combination bortezomib bevacizumab carboplatin first line therapy patients metastatic nonsmall cell lung cancer nsclc phase ii study combination first line setting conducted order properly estimate efficacy safety regimen form basis future studies comparing combination considered standard regimen first line therapy patients nsclc carboplatin paclitaxel bevacizumab